These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51. PCSK9 antibodies: A new class of lipid-lowering drugs. Gouni-Berthold I Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300 [TBL] [Abstract][Full Text] [Related]
52. Is there a problem with ezetimibe or just ENHANCEd hype? Whayne TF Angiology; 2008 Dec-2009 Jan; 59(6):661-3. PubMed ID: 18796445 [No Abstract] [Full Text] [Related]
53. PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all : Editorial to: "Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/Dl or Higher" by Henry N. Ginsberg et Al. Stein EA Cardiovasc Drugs Ther; 2016 Oct; 30(5):427-431. PubMed ID: 27669716 [No Abstract] [Full Text] [Related]
54. Back to basics: PCSK9 as a new target for the LDL receptor. Corral P Arq Bras Cardiol; 2014 Jan; 102(1):e5-8. PubMed ID: 24652095 [No Abstract] [Full Text] [Related]
56. The promises of PCSK9 inhibition. Petrides F; Shearston K; Chatelais M; Guilbaud F; Meilhac O; Lambert G Curr Opin Lipidol; 2013 Aug; 24(4):307-12. PubMed ID: 23817198 [TBL] [Abstract][Full Text] [Related]
57. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9. Page MM; Stefanutti C; Sniderman A; Watts GF Clin Sci (Lond); 2015 Jul; 129(1):63-79. PubMed ID: 25881720 [TBL] [Abstract][Full Text] [Related]
58. One-shot, one cure with genome editing for dyslipidemia. Gupta RM Circ Cardiovasc Genet; 2014 Dec; 7(6):967-8. PubMed ID: 25516627 [No Abstract] [Full Text] [Related]
59. Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia. Lee P; Hegele RA Expert Opin Investig Drugs; 2013 Nov; 22(11):1411-23. PubMed ID: 23889692 [TBL] [Abstract][Full Text] [Related]
60. Biomedicine. Lowering LDL--not only how low, but how long? Brown MS; Goldstein JL Science; 2006 Mar; 311(5768):1721-3. PubMed ID: 16556829 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]